French diagnostics company bioMérieux (Euronext Paris:BIM) announced on Thursday that it has introduced two equine endocrinology immunoassays -- VIDAS Equine INSULIN and VIDAS Equine ACTH -- designed to deliver laboratory-standard results directly at the point of care.

VIDAS Equine INSULIN provides insulin level measurements in about 20 minutes to support diagnosis and management of Equine Metabolic Syndrome, while VIDAS Equine ACTH offers hormone dysregulation testing related to Pituitary Pars Intermedia Dysfunction in approximately 45 minutes.

The company noted that 18% to 27% of horses over 15 years of age exhibit symptoms linked to Cushing's or insulin dysregulation, conditions associated with increased risk of complications such as chronic laminitis.

bioMérieux stated that the rapid, easy-to-use assays are intended to strengthen early detection and improve clinical decision-making in veterinary practices.

The tests will be available in the UK through the VIDAS KUBE immunoanalyser, marking the first equine-focused platform offering this level of hormone testing at the point of care.

Following its June launch of the VETFIRE PCR respiratory test, the company continues to apply its human diagnostics expertise to veterinary healthcare to reduce wait times and accelerate treatment decisions.